The importance of robust genomic testing for patients - Takeaways - MDSpire

The importance of robust genomic testing for patients

Misako Nagasaka, MD, PhD shared how precision oncology has fundamentally shifted the landscape through the identification of actionable genomic targets for lung cancer treatment.

  • June 25, 2026

Share

  • 1

    Misako Nagasaka, MD, PhD, emphasizes the role of precision oncology in identifying actionable genomic targets for lung cancer treatment.

  • 2

    Robust genomic testing is crucial for ensuring patients receive appropriate targeted inhibitors for lung cancer.

  • 3

    Median progression-free survival for ALK-positive non-small cell lung cancer treated with lorlatinib has not yet been reached.

  • 4

    Patients receiving lorlatinib may achieve long-term, durable remission, providing reassurance in treatment outcomes.

  • 5

    Third-generation ALK inhibitors have transformed lung cancer from a devastating diagnosis into a manageable chronic condition.

Original Source(s)

The importance of robust genomic testing for patients

  • June 25, 2026

Related Content

ASCO26: Julia Rotow, MD, Silevertinib in Lung Cancer

Dana-Farber Cancer Institute's Dr. Julia Rotow reported on a study looking at silevertinib, with data showing it may offer a new first-line option for hard-to-treat EGFR non-small cell lung cancer variants, with encouraging brain activity and manageable side effects.

  • July 1, 2026

  • 1 min
Incidental thyroid carcinoma in surgically treated multinodular goiter: a retrospective study

FDA says Zyn can market its pouches as safer than cigarettes